California-based Glaukos, recently cited as one of the top 50 venture-funded firms by The Wall Street Journal, specializes in developing titanium microstents and other devices designed to treat glaucoma. The company is seeking FDA approval for its iStent product, which already is approved in Europe, President and CEO Thomas Burns said.

Related Summaries